Lundbeck posts 12% growth in revenue and 56% in EPS

7 November 2018

Danish CNS specialist Lundbeck (LUND: CO) reported a strong set of financial results this morning, and up its guidance, but failed to impress investors, as the firm’s shares dipped 2.69% to 293.20 Danish kroner in early trading.

Revenue reached 13.92 billion kroner ($2.12 billion) in the first nine months of 2018 representing an increase of 8% (12% in local currencies) compared to the same period in 2017.

Earnings before interest and taxes (EBIT) increased 28% to 4.45 billion and the EBIT margin reached 32.0% compared to 27.1% in 2017. Earnings per share (EPS) grew 56% to 16.38 kroner in the period compared to 10.49 kroner the year before.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK